Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ligufalimab by Akeso for Myelodysplastic Syndrome: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...
Ligufalimab by Akeso for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Ligufalimab by Akeso for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Ligufalimab by Akeso for Oropharyngeal Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Ligufalimab by Akeso for Laryngeal Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Ligufalimab by Akeso for Hypopharyngeal Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
Ligufalimab by Akeso for Hepatocellular Carcinoma: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Ligufalimab by Akeso for Cervical Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Ligufalimab by Akeso for Colorectal Cancer: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Akeso's Ligufalimab?
Ligufalimab is a monoclonal antibody commercialized by Akeso, with a leading Phase II program in Colorectal Cancer. According to Globaldata,...